These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32248765)

  • 21. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
    Saleh L; van den Meiracker AH; Geensen R; Kaya A; Roeters van Lennep JE; Duvekot JJ; Verdonk K; Steegers EAP; Russcher H; Danser AHJ; Visser W
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):751-757. PubMed ID: 28600845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.
    Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B
    Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
    Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
    Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy.
    Birdir C; Droste L; Fox L; Frank M; Fryze J; Enekwe A; Köninger A; Kimmig R; Schmidt B; Gellhaus A
    Pregnancy Hypertens; 2018 Apr; 12():124-128. PubMed ID: 29674192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of adverse maternal outcomes of early severe preeclampsia.
    Mirkovic L; Tulic I; Stankovic S; Soldatovic I
    Pregnancy Hypertens; 2020 Oct; 22():144-150. PubMed ID: 32979729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.
    MacDonald TM; Tran C; Kaitu'u-Lino TJ; Brennecke SP; Hiscock RJ; Hui L; Dane KM; Middleton AL; Cannon P; Walker SP; Tong S
    BMC Pregnancy Childbirth; 2018 Aug; 18(1):354. PubMed ID: 30170567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between the high soluble fms-like tyrosine kinase-1 to placental growth factor ratio and adverse outcomes in asymptomatic women with early-onset fetal growth restriction.
    Shinohara S; Uchida Y; Kasai M; Sunami R
    Hypertens Pregnancy; 2017 Aug; 36(3):269-275. PubMed ID: 28737473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of the sFlt-1/PlGF ratio to rule out preeclampsia requiring delivery in women with suspected disease. Is the evidence reproducible?
    Sabrià E; Lequerica-Fernández P; Ganuza PL; Ángeles EE; Escudero AI; Martínez-Morillo E; Alvárez FV
    Clin Chem Lab Med; 2018 Jan; 56(2):303-311. PubMed ID: 28841572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction.
    Herraiz I; Dröge LA; Gómez-Montes E; Henrich W; Galindo A; Verlohren S
    Obstet Gynecol; 2014 Aug; 124(2 Pt 1):265-273. PubMed ID: 25004342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary placental growth factor in preeclampsia and fetal growth restriction: An alternative to circulating biomarkers?
    Zhang K; Zen M; Popovic NL; Lee VW; Alahakoon TI
    J Obstet Gynaecol Res; 2019 Sep; 45(9):1828-1836. PubMed ID: 31257726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrauterine growth restriction, soluble fms-like tyrosine kinase-1 to placental growth factor ratio increase and preeclampsia.
    Boulanger H; Drouin D; Largilliere C; Lefèvre G
    J Gynecol Obstet Hum Reprod; 2019 Oct; 48(8):695-697. PubMed ID: 31085278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Similar Pro- and Antiangiogenic Profiles Close to Delivery in Different Clinical Presentations of Two Pregnancy Syndromes: Preeclampsia and Fetal Growth Restriction.
    Dymara-Konopka W; Laskowska M; Grywalska E; Hymos A; Błażewicz A; Leszczyńska-Gorzelak B
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of sFlt/PlGF ratio with severity of preeclampsia in an Indian population.
    Kumar N; Das V; Agarwal A; Agrawal S
    AJOG Glob Rep; 2023 May; 3(2):100177. PubMed ID: 36911235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of preterm birth in growth-restricted and appropriate-for-gestational-age infants using maternal PlGF and the sFlt-1/PlGF ratio-A prospective study.
    Hong J; Crawford K; Cavanagh E; da Silva Costa F; Kumar S
    BJOG; 2024 Jul; 131(8):1089-1101. PubMed ID: 38196326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for fetal growth restriction using ultrasound and the sFLT1/PlGF ratio in nulliparous women: a prospective cohort study.
    Gaccioli F; Sovio U; Cook E; Hund M; Charnock-Jones DS; Smith GCS
    Lancet Child Adolesc Health; 2018 Aug; 2(8):569-581. PubMed ID: 30119716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predictive value of the sFlt-1/PlGF ratio in suspected preeclampsia in a New Zealand population: A prospective cohort study.
    Hughes RCE; Phillips I; Florkowski CM; Gullam J
    Aust N Z J Obstet Gynaecol; 2023 Feb; 63(1):34-41. PubMed ID: 35670085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes.
    Salahuddin S; Wenger JB; Zhang D; Thadhani R; Karumanchi SA; Rana S
    Hypertens Pregnancy; 2016 Aug; 35(3):330-45. PubMed ID: 27028795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should angiogenic markers be included in diagnostic criteria of superimposed pre-eclampsia in women with chronic hypertension?
    Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
    Ultrasound Obstet Gynecol; 2022 Feb; 59(2):192-201. PubMed ID: 34165863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. sFlt-1/PlGF ratio for the prediction of delivery within 48 hours and adverse outcomes in expectantly managed early-onset preeclampsia.
    Simón E; Permuy C; Sacristán L; Zamoro-Lorenci MJ; Villalaín C; Galindo A; Herraiz I
    Pregnancy Hypertens; 2020 Oct; 22():17-23. PubMed ID: 32707515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia.
    Nzelu D; Biris D; Karampitsakos T; Nicolaides KK; Kametas NA
    Am J Obstet Gynecol; 2020 Apr; 222(4):374.e1-374.e9. PubMed ID: 31705883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.